CHF Solutions Renamed Nuwellis As It Expands Beyond Heart Failure Therapy
The company is expanding beyond its traditional focus on heart failure to bring its Aquadex fluid-management technology to more critical care and pediatric patients. Nuwellis’ new ticker symbol on NASDAQ is NUWE.
You may also be interested in...
Nestor Jaramillo, who just finished his first quarter as CEO of CHF Solutions, told Medtech Insight how his company is making its Aquadex ultrafiltration technology part of the standard of care for heart failure patients and others with dangerous fluid overload.
The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.